285 related articles for article (PubMed ID: 30555229)
1. Liposomal drug delivery in an in vitro 3D bone marrow model for multiple myeloma.
Braham MV; Deshantri AK; Minnema MC; Öner FC; Schiffelers RM; Fens MH; Alblas J
Int J Nanomedicine; 2018; 13():8105-8118. PubMed ID: 30555229
[TBL] [Abstract][Full Text] [Related]
2. In vivo evaluation of CD38 and CD138 as targets for nanoparticle-based drug delivery in multiple myeloma.
Omstead DT; Mejia F; Sjoerdsma J; Kim B; Shin J; Khan S; Wu J; Kiziltepe T; Littlepage LE; Bilgicer B
J Hematol Oncol; 2020 Nov; 13(1):145. PubMed ID: 33138841
[TBL] [Abstract][Full Text] [Related]
3. The liposomal formulation of doxorubicin.
Abraham SA; Waterhouse DN; Mayer LD; Cullis PR; Madden TD; Bally MB
Methods Enzymol; 2005; 391():71-97. PubMed ID: 15721375
[TBL] [Abstract][Full Text] [Related]
4. Modeling multiple myeloma-bone marrow interactions and response to drugs in a 3D surrogate microenvironment.
Belloni D; Heltai S; Ponzoni M; Villa A; Vergani B; Pecciarini L; Marcatti M; Girlanda S; Tonon G; Ciceri F; Caligaris-Cappio F; Ferrarini M; Ferrero E
Haematologica; 2018 Apr; 103(4):707-716. PubMed ID: 29326121
[TBL] [Abstract][Full Text] [Related]
5. Hyaluronic acid modified pH-sensitive liposomes for targeted intracellular delivery of doxorubicin.
Paliwal SR; Paliwal R; Agrawal GP; Vyas SP
J Liposome Res; 2016 Dec; 26(4):276-87. PubMed ID: 26784587
[TBL] [Abstract][Full Text] [Related]
6. Tracking Drugs and Lipids: Quantitative Mass Spectrometry Imaging of Liposomal Doxorubicin Delivery and Bilayer Fate in Three-Dimensional Tumor Models.
Lopez A; Holbrook JH; Kemper GE; Lukowski JK; Andrews WT; Hummon AB
Anal Chem; 2024 Jun; 96(22):9254-9261. PubMed ID: 38778440
[TBL] [Abstract][Full Text] [Related]
7. Engineered peptides for the development of actively tumor targeted liposomal carriers of doxorubicin.
Shahin M; Soudy R; El-Sikhry H; Seubert JM; Kaur K; Lavasanifar A
Cancer Lett; 2013 Jul; 334(2):284-92. PubMed ID: 23073474
[TBL] [Abstract][Full Text] [Related]
8. Liposomal dexamethasone inhibits tumor growth in an advanced human-mouse hybrid model of multiple myeloma.
Deshantri AK; Fens MH; Ruiter RWJ; Metselaar JM; Storm G; van Bloois L; Varela-Moreira A; Mandhane SN; Mutis T; Martens ACM; Groen RWJ; Schiffelers RM
J Control Release; 2019 Feb; 296():232-240. PubMed ID: 30682443
[TBL] [Abstract][Full Text] [Related]
9. A novel 3D mesenchymal stem cell model of the multiple myeloma bone marrow niche: biologic and clinical applications.
Jakubikova J; Cholujova D; Hideshima T; Gronesova P; Soltysova A; Harada T; Joo J; Kong SY; Szalat RE; Richardson PG; Munshi NC; Dorfman DM; Anderson KC
Oncotarget; 2016 Nov; 7(47):77326-77341. PubMed ID: 27764795
[TBL] [Abstract][Full Text] [Related]
10. Tumor microenvironment-targeted nanoparticles loaded with bortezomib and ROCK inhibitor improve efficacy in multiple myeloma.
Federico C; Alhallak K; Sun J; Duncan K; Azab F; Sudlow GP; de la Puente P; Muz B; Kapoor V; Zhang L; Yuan F; Markovic M; Kotsybar J; Wasden K; Guenthner N; Gurley S; King J; Kohnen D; Salama NN; Thotala D; Hallahan DE; Vij R; DiPersio JF; Achilefu S; Azab AK
Nat Commun; 2020 Nov; 11(1):6037. PubMed ID: 33247158
[TBL] [Abstract][Full Text] [Related]
11. Enhanced Cytotoxicity of Folic Acid-Targeted Liposomes Co-Loaded with C6 Ceramide and Doxorubicin: In Vitro Evaluation on HeLa, A2780-ADR, and H69-AR Cells.
Sriraman SK; Pan J; Sarisozen C; Luther E; Torchilin V
Mol Pharm; 2016 Feb; 13(2):428-37. PubMed ID: 26702994
[TBL] [Abstract][Full Text] [Related]
12. Tumor targeting using anti-her2 immunoliposomes.
Park JW; Kirpotin DB; Hong K; Shalaby R; Shao Y; Nielsen UB; Marks JD; Papahadjopoulos D; Benz CC
J Control Release; 2001 Jul; 74(1-3):95-113. PubMed ID: 11489487
[TBL] [Abstract][Full Text] [Related]
13. Liposomal daunorubicin: in vitro and in vivo efficacy in multiple myeloma.
Pratt G; Wiles ME; Rawstron AC; Davies FE; Fenton JA; Proffitt JA; Child JA; Smith GM; Morgan GJ
Hematol Oncol; 1998 Jun; 16(2):47-55. PubMed ID: 10065112
[TBL] [Abstract][Full Text] [Related]
14. 3D tissue-engineered bone marrow as a novel model to study pathophysiology and drug resistance in multiple myeloma.
de la Puente P; Muz B; Gilson RC; Azab F; Luderer M; King J; Achilefu S; Vij R; Azab AK
Biomaterials; 2015 Dec; 73():70-84. PubMed ID: 26402156
[TBL] [Abstract][Full Text] [Related]
15. Liposomal delivery improves the growth-inhibitory and apoptotic activity of low doses of gemcitabine in multiple myeloma cancer cells.
Celia C; Malara N; Terracciano R; Cosco D; Paolino D; Fresta M; Savino R
Nanomedicine; 2008 Jun; 4(2):155-66. PubMed ID: 18430611
[TBL] [Abstract][Full Text] [Related]
16. Endosteal and Perivascular Subniches in a 3D Bone Marrow Model for Multiple Myeloma.
Braham MVJ; Ahlfeld T; Akkineni AR; Minnema MC; Dhert WJA; Öner FC; Robin C; Lode A; Gelinsky M; Alblas J
Tissue Eng Part C Methods; 2018 May; 24(5):300-312. PubMed ID: 29652626
[TBL] [Abstract][Full Text] [Related]
17. Lipoic acid-derived cross-linked liposomes for reduction-responsive delivery of anticancer drug.
Ling L; Ismail M; Du Y; Yao C; Li X
Int J Pharm; 2019 Apr; 560():246-260. PubMed ID: 30769133
[TBL] [Abstract][Full Text] [Related]
18. Liposomal carfilzomib nanoparticles effectively target multiple myeloma cells and demonstrate enhanced efficacy in vivo.
Ashley JD; Stefanick JF; Schroeder VA; Suckow MA; Alves NJ; Suzuki R; Kikuchi S; Hideshima T; Anderson KC; Kiziltepe T; Bilgicer B
J Control Release; 2014 Dec; 196():113-21. PubMed ID: 25312543
[TBL] [Abstract][Full Text] [Related]
19. The bone marrow stromal microenvironment influences myeloma therapeutic response in vitro.
Cheung WC; Van Ness B
Leukemia; 2001 Feb; 15(2):264-71. PubMed ID: 11236942
[TBL] [Abstract][Full Text] [Related]
20. Aptamer-drug conjugate: targeted delivery of doxorubicin in a HER3 aptamer-functionalized liposomal delivery system reduces cardiotoxicity.
Dou XQ; Wang H; Zhang J; Wang F; Xu GL; Xu CC; Xu HH; Xiang SS; Fu J; Song HF
Int J Nanomedicine; 2018; 13():763-776. PubMed ID: 29440899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
